Colleen F. Reitan's most recent trade in Myriad Genetics, Inc. was a trade of 59,701 Common Stock done . Disclosure was reported to the exchange on June 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Myriad Genetics Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2026 | 59,701 | 152,030 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2026 | 1,441 | 1,441 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2026 | 671 | 1,446 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2025 | 18,000 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.65 per share. | 09 Sep 2025 | 18,000 | 18,775 (0%) | 0% | 100.7 | 1,811,700 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 461.92 per share. | 09 Sep 2025 | 2,290 | 11,076 (0%) | 0% | 461.9 | 1,057,797 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 458.86 per share. | 09 Sep 2025 | 1,888 | 15,242 (0%) | 0% | 458.9 | 866,328 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 463.00 per share. | 09 Sep 2025 | 1,652 | 9,424 (0%) | 0% | 463 | 764,876 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 457.44 per share. | 09 Sep 2025 | 1,645 | 17,130 (0%) | 0% | 457.4 | 752,489 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 478.67 per share. | 09 Sep 2025 | 1,450 | 2,186 (0%) | 0% | 478.7 | 694,072 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 459.73 per share. | 09 Sep 2025 | 1,403 | 13,839 (0%) | 0% | 459.7 | 645,001 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 479.55 per share. | 09 Sep 2025 | 1,386 | 800 (0%) | 0% | 479.5 | 664,656 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 477.47 per share. | 09 Sep 2025 | 1,183 | 3,636 (0%) | 0% | 477.5 | 564,847 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 476.31 per share. | 09 Sep 2025 | 972 | 4,819 (0%) | 0% | 476.3 | 462,973 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 474.85 per share. | 09 Sep 2025 | 951 | 5,791 (0%) | 0% | 474.8 | 451,582 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 474.22 per share. | 09 Sep 2025 | 838 | 6,742 (0%) | 0% | 474.2 | 397,396 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 472.82 per share. | 09 Sep 2025 | 823 | 7,580 (0%) | 0% | 472.8 | 389,131 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 464.36 per share. | 09 Sep 2025 | 799 | 8,625 (0%) | 0% | 464.4 | 371,024 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 460.71 per share. | 09 Sep 2025 | 473 | 13,366 (0%) | 0% | 460.7 | 217,916 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 471.25 per share. | 09 Sep 2025 | 222 | 8,403 (0%) | 0% | 471.3 | 104,618 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 481.00 per share. | 09 Sep 2025 | 25 | 775 (0%) | 0% | 481 | 12,025 | Common Stock |
| Myriad Genetics Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 49,796 | 92,329 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 27.95 per share. | 03 Sep 2024 | 46,012 | 42,533 (0%) | 0% | 27.9 | 1,285,851 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2024 | 1,558 | 1,558 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2024 | 775 | 775 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 232.86 per share. | 29 Aug 2024 | 36 | 0 (0%) | 0% | 232.9 | 8,383 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Purchase of securities on an exchange or from another person at price $ 286.00 per share. | 29 Aug 2024 | 32 | 32 (0%) | 0% | 286 | 9,152 | Common Stock |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Purchase of securities on an exchange or from another person at price $ 302.75 per share. | 29 Aug 2024 | 4 | 36 (0%) | 0% | 302.8 | 1,211 | Common Stock |
| Myriad Genetics Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 88,545 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
| Myriad Genetics Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,151 | 72,850 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | |
| Myriad Genetics Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 57,699 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 5,153 | 5,153 | - | - | Stock Option (right to buy) |